Breast Cancer Recurrence
Breast Cancer Recurrence - Related Videos
10:10
Long-term Culture of Human Breast Cancer Specimens and Their Analysis Using Optical Projection Tomography
0 Views •
Cited by 11 •
2011
We have developed a collagen-based in vitro assay which promotes proliferation and invasion from samples of all breast cancer subtypes. Optical Projection Tomography, a three dimensional microscopy technique was utilised to visualise and quantify tumour expansion. This assay may be used to quantify drug response of individual tumour samples.
08:11
An Orthotopic Mouse Model of Spontaneous Breast Cancer Metastasis
0 Views •
Cited by 83 •
2016
An orthotopic breast cancer primary tumor model and surgical removal of primary tumor to extend mouse life to generate spontaneous metastasis are described. The tumor growth and progression are monitored and quantified by luciferase fluorescence imaging.
07:13
Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
0 Views •
Cited by 27 •
2014
Activation of latent mutations with adenovirus-Cre into the mammary ductal system results in a clinically relevant metastatic breast cancer. Incorporation of a YFP promoter allows tracking of distal metastatic tumor cells. This model is useful to study latent metastasis, anti-tumor immunity, and for designing novel immunotherapies to treat breast cancer.
07:47
Studying the Role of Alveolar Macrophages in Breast Cancer Metastasis
0 Views •
Cited by 7 •
2016
Here we describe the model and approach to study functions of pulmonary alveolar macrophages in cancer metastasis. To demonstrate the role of these cells in metastasis, the syngeneic (4T1) model of breast cancer in conjunction with the depletion of alveolar macrophage with clodronate liposomes was used.
09:22
Invasive Behavior of Human Breast Cancer Cells in Embryonic Zebrafish
0 Views •
Cited by 44 •
2017
Here, we describe xenograft zebrafish models using two different injection sites, i.e., perivitelline space and duct of Cuvier, to investigate the invasive behavior and to assess the intravasation and extravasation potential of human breast cancer cells, respectively.
FAQs
Residual cancer cells can remain after surgery, radiation, or systemic therapy even when they are too few to detect. Some may enter a dormant state, meaning they do not actively grow for a period of time. If conditions later become favorable, these cells can resume growth, providing a biological explanation for recurrence after an apparently successful initial treatment.
Risk assessment draws on several dimensions rather than a single finding. Clinicians consider tumor biology, the original stage, treatments already given, and where a later abnormality appears. Together, these factors help distinguish the clinical context of a possible recurrence and support decisions about surveillance and treatment. They also help explain why recurrence risk and management can differ among patients.
A return in the original breast, nearby tissues, lymph nodes, or distant organs represents a different anatomic context for clinical evaluation. Location is therefore a central part of interpreting a new finding, alongside tumor biology, stage, and treatment history. This information helps clinicians characterize the recurrence and select an appropriate therapeutic approach.
Minimal residual disease refers to cancer cells that remain after treatment but are below the level of detection. Studying it may clarify how recurrence begins, while research into treatment resistance examines why some residual cells survive therapy. These areas connect the biology of recurrence with efforts to identify patients at risk and develop strategies that prevent or delay relapse.
Follow-up care supports surveillance and risk assessment after initial treatment. It brings together evaluation of new symptoms or imaging findings with information about tumor biology, original stage, treatment history, and possible recurrence location. This approach helps clinicians identify findings requiring further clinical attention and supports informed management decisions without relying on a single observation.
Treatment selection is informed by tumor biology, stage, prior treatment, and the location of recurrence. These factors provide clinical context for choosing an approach rather than relying on the fact of recurrence alone. In medicine, linking the new disease pattern to the earlier cancer and its treatment history helps clinicians tailor management to the patient’s situation.
Research on breast cancer recurrence extends beyond treating an established return. Investigators examine minimal residual disease, dormant residual cells, and treatment resistance to understand why relapse can occur after initial therapy. The broader goal is to develop strategies that prevent recurrence or delay it, while improving how clinicians assess risk and interpret findings during follow-up care.